{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:23:58Z","timestamp":1779877438248,"version":"3.53.1"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of cladribine in treating pulmonary Langerhans cell histiocytosis (PLCH) has been suggested in select case reports. Treatment-related malignancies remain a concern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this phase II trial, the efficacy and safety of cladribine was evaluated in symptomatic PLCH patients with airflow obstruction and\/or a decrease in lung function within the previous year. Cladribine was administered for 4 monthly cycles combined with infectious prophylaxis. Patients were followed up every 3\u2005months during the first year to assess efficacy and then until 48\u2005months. The primary end-point was the cumulative incidence of response to treatment at 6\u2005months, defined as \u226510% improvement in forced vital capacity (FVC) and\/or forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), with an increase of \u2265200\u2005mL in the absolute value of FEV\n                      <jats:sub>1<\/jats:sub>\n                      . The study was registered with\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01473797\">NCT01473797<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>10 patients (six men; median (interquartile range (IQR)) age 37 (33\u201347.5)\u2005years; six current smokers) were included. The cumulative incidence of response to treatment at 6\u2005months was 70% (95% CI 28.4\u201390.4%). The response to cladribine was associated with a median (IQR) decrease of 14.9 (10.5\u201323.5) points in the St George's Respiratory Questionnaire Total score. At 12\u2005months, five patients were still responders. The median (IQR) duration of infection prophylaxis was 11.8 (11.7\u201329)\u2005months. One patient died before the 12-month visit. The remaining patients were alive at 48\u2005months. No malignancies were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cladribine improved lung function in half of the patients at 1\u2005year of follow-up and was well tolerated overall.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01464-2025","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:20:14Z","timestamp":1769700014000},"page":"2501464","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of cladribine in adult pulmonary Langerhans cell histiocytosis: a phase II study"],"prefix":"10.1183","volume":"67","author":[{"given":"Amira","family":"Benattia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Lorillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"de Margerie-Mellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-5622","authenticated-orcid":false,"given":"Philippe","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-9941","authenticated-orcid":false,"given":"Charles-Hugo","family":"Marquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-7444","authenticated-orcid":false,"given":"Abdellatif","family":"Tazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026052103350782000_67.5.2501464.1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MCP.0000000000000988","article-title":"Pulmonary Langerhans cell histiocytosis \u2013 an update on pathogenesis and treatment","volume":"29","author":"Jouenne","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026052103350782000_67.5.2501464.2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210125"},{"key":"2026052103350782000_67.5.2501464.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01017-2021"},{"key":"2026052103350782000_67.5.2501464.4","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00864-2024"},{"key":"2026052103350782000_67.5.2501464.5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-017-0651-z","article-title":"Vinblastine chemotherapy in adult patients with Langerhans cell histiocytosis: a multicenter retrospective study","volume":"12","author":"Tazi","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2026052103350782000_67.5.2501464.6","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.26119","article-title":"Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis","volume":"96","author":"Goyal","year":"2021","journal-title":"Am J Hematol"},{"key":"2026052103350782000_67.5.2501464.7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16449","article-title":"Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review","volume":"189","author":"Neel","year":"2020","journal-title":"Br J Haematol"},{"key":"2026052103350782000_67.5.2501464.8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjh.16944","article-title":"Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment","volume":"191","author":"Barkaoui","year":"2020","journal-title":"Br J Haematol"},{"key":"2026052103350782000_67.5.2501464.9","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","article-title":"Cladribine activity in adult Langerhans-cell histiocytosis","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"key":"2026052103350782000_67.5.2501464.10","first-page":"16586","article-title":"Cladribine treatment in patients with pulmonary Langerhans cell histiocytosis","volume":"133","author":"Radzikowska","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"2026052103350782000_67.5.2501464.11","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00089-2017"},{"key":"2026052103350782000_67.5.2501464.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00146114"},{"key":"2026052103350782000_67.5.2501464.13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0191-8"},{"key":"2026052103350782000_67.5.2501464.14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.186.9.930"},{"key":"2026052103350782000_67.5.2501464.15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cei.12109","article-title":"2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells","volume":"173","author":"Singh","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2026052103350782000_67.5.2501464.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114865"},{"key":"2026052103350782000_67.5.2501464.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-757823"},{"key":"2026052103350782000_67.5.2501464.18","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3390\/cells10123488","article-title":"Immunomodulatory effects associated with cladribine treatment","volume":"10","author":"Fissolo","year":"2021","journal-title":"Cells"},{"key":"2026052103350782000_67.5.2501464.19","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200108000-00002"},{"key":"2026052103350782000_67.5.2501464.20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/ped.13792","article-title":"Cladribine-related myelodysplastic syndrome in Langerhans cell histiocytosis","volume":"61","author":"Oh","year":"2019","journal-title":"Pediatr Int"},{"key":"2026052103350782000_67.5.2501464.21","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.565097"},{"key":"2026052103350782000_67.5.2501464.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0249-2"},{"key":"2026052103350782000_67.5.2501464.23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2011.570395","article-title":"Alternative methods of cladribine administration","volume":"52","author":"Lauria","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2026052103350782000_67.5.2501464.24","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"key":"2026052103350782000_67.5.2501464.25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2023021212","article-title":"BRAF\n               V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis","volume":"142","author":"Acosta-Medina","year":"2023","journal-title":"Blood"},{"key":"2026052103350782000_67.5.2501464.26","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"2026052103350782000_67.5.2501464.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2490"},{"key":"2026052103350782000_67.5.2501464.28","first-page":"132","article-title":"A prospective clinical multicentre study on adult pulmonary Langerhans\u2019 cell histiocytosis","volume":"29","author":"Schonfeld","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026052103350782000_67.5.2501464.29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00259-016-3521-3","article-title":"18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis","volume":"44","author":"Obert","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026052103350782000_67.5.2501464.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00210711"},{"key":"2026052103350782000_67.5.2501464.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01190-2019"},{"key":"2026052103350782000_67.5.2501464.32","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200507-065JS"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01464-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:35:16Z","timestamp":1779359716000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01464-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/13993003.01464-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01464-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}